Tissue Solutions Celebrates Six Years of Operations - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Tissue Solutions Celebrates Six Years of Operations

Tissue Solutions Ltd, which sources human biomaterials for pre-clinical research, is celebrating six years in business.

Tissue Solutions Ltd was founded in 2007 by Morag McFarlane and Ann Cooreman. Six years on, the company is now an ISO 9001:2008 accredited company that works worldwide delivering ethically sourced biological samples required for research, including cells, tissues and biofluids.

The company sources ethically acquired and fully consented quality human tissue from an extensive global network of collaborating partners. These range from direct hospital sources to commercial bio banks, charities and prospective post mortem organ and tissue collection agencies.

In the past six years, Tissue Solutions has grown steadily year on year gaining an international reputation as an ethical and high quality provider. They have increased both turnover and head count, outgrown two premises and are now based in the West of Scotland Science Park. The company has access to in excess of 110 million samples for pharmaceutical and biotechnology clientsworldwide supporting target identification & validation, biomarker studies, companion diagnostics and safety testing.

"We like to think of ourselves as part of our clients tissue acquisition team," said Morag McFarlane, founder and CSO. "Our tissue service is a customised approach; based entirely on what the client needs for a specific project and we work directly with our clients to source samples that are suitable for their specific platform or application.

"During the last six years we have experienced exponential growth due to the ever increasing demand for human tissue mostly for pre-clinical research but more recently also for later stage projects."

Tissue Solutions Ltd can now providebanked and freshly collected biospecimens from both normal donors and patients across a full range of disease areas including cancer, autoimmune disorders, CNS/Neurodegeneration, inflammation, cardiovascular, metabolic disorders, infectious diseases, and blood disorders.

More About This Company